10-Q quarterly report · filed Nov 12, 2026

Fulcrum Therapeutics, Inc. (FULC) Q3 2026 10-Q Quarterly Report

Short answer

Fulcrum Therapeutics, Inc. (FULC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$11M
+44.2% YoY · +58.2% QoQ
EPS (diluted)
−$0.14
+54.8% YoY · +58.8% QoQ

Source: XBRL data from the Fulcrum Therapeutics, Inc. (FULC) Q3 2026 10-Q on SEC EDGAR. USD.

Fulcrum Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales
  • Net loss $10.9M vs $19.6M YoY, operating expenses $13.9M vs $21.9M
  • Pociredir R&D expenses $1.9M vs $5.4M YoY, the largest program expense
  • Cash, equivalents and securities $306.5M at September 30, 2026
  • Operating cash used $48.2M vs $43.3M YoY, merger expected Q4 2026 with $275M dividend and $7.0M asset sale

Risk Factors

  • Smaller reporting company status: Item 1A risk-factor disclosure omitted under Rule 12b-2
  • No newly added, updated, regulatory, operational, competitive, market, or financial risks disclosed this quarter

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Fulcrum Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.